|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500099033 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-18 08:35:51 |
|
注册时间: Date of Registration: |
2025-03-18 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
宫安康?用于人流术后子宫内膜修复作用的安全性和有效性:一项前瞻性、多中心、单臂临床研究 |
|
Public title: |
Safety and efficacy of MateRegen? for endometrial repair after abortion: a prospective, multicenter, single-arm clinical study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
宫安康?用于人流术后子宫内膜修复作用的安全性和有效性:一项前瞻性、多中心、单臂临床研究 |
|
Scientific title: |
Safety and efficacy of MateRegen? for endometrial repair after abortion: a prospective, multicenter, single-arm clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
江静 |
研究负责人: |
江静 |
|
Applicant: |
Jing Jiang |
Study leader: |
Jing Jiang |
|
申请注册联系人电话: Applicant telephone: |
+86 137 8030 7399 |
研究负责人电话:
Study leader's |
+86 137 8030 7399 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jiangjing011@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
jiangjing011@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河北省石家庄市和平西路215号 |
研究负责人通讯地址: |
河北省石家庄市和平西路215号 |
|
Applicant address: |
No. 215, Heping West Road, Shijiazhuang, Hebei, China |
Study leader's address: |
No. 215, Heping West Road, Shijiazhuang, Hebei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河北医科大学第二医院 |
||
|
Applicant's institution: |
The Second Hospital of Hebei Medical University |
||
|
研究负责人所在单位: |
河北医科大学第二医院 |
||
|
Affiliation of the Leader: |
The Second Hospital of Hebei Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-C103 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河北医科大学第二医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee of the second hospital of Hebei Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-16 00:00:00 | ||
|
伦理委员会联系人: |
孙惠莲 |
||
|
Contact Name of the ethic committee: |
Huilian Sun |
||
|
伦理委员会联系地址: |
河北省石家庄市和平西路215号 |
||
|
Contact Address of the ethic committee: |
No. 215, Heping West Road, Shijiazhuang, Hebei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 311 6600 2826 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
河北医科大学第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Hospital of Hebei Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
石家庄市鹿泉区槐安西路501号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.501, Huai'an West Road, Luquan District, Shijiazhuang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
子宫腔粘连 |
||||||||||||||||||||||
|
Target disease: |
Surgical Abortion |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本临床研究的目的是对宫腔用交联透明质酸钠凝胶 (宫安康?)在人流手术后对子宫内膜修复作用的效果进行评价。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this clinical study was to evaluate the effect of intrauterine cross-linked sodium hyaluronate gel (MateRegen?) on endometrial repair after abortion. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 经检查确定进行人流手术(负压吸引术)的患者; 2. 年龄18-45周岁; 3. 无严重系统性疾病; 4. 取得参加研究的知情同意书; 5. 依从性良好,术后愿意并且能够按要求进行随访观察; 6. 同时符合以下两条(1)孕周<10孕周;(2)术前超声提示胎囊≥1cm或胎芽<3.0cm。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients who have been examined and determined to undergo abortion (negative pressure suction); 2. Aged 18-45 years old; 3. Without serious systemic diseases. 4. Obtain informed consent to participate in the study; 5. Have good compliance and are willing and able to follow up after the operation as required; 6. Meet the following two criteria: (1) gestational week <10 weeks; (2) preoperative ultrasound suggests that the fetal sac is >=1cm or the fetal bud is <3.0cm. |
||||||||||||||||||||||
|
排除标准: |
1. 合并其他妇科疾病(例如:子宫肌瘤、子宫腺肌病、宫腔粘连病史); 2. 合并严重心、肝、肾等重要脏器功能障碍; 3. 既往月经失调,多囊卵巢综合症; 4. 透明质酸过敏; 5. 其他研究者认为不符合入组的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combination of other gynecologic diseases (e.g., history of uterine fibroids, adenomyosis, uterine adhesions); 2. Comorbidity with severe cardiac, hepatic, renal and other vital organ dysfunction; 3. Pre-existing menstrual disorders, polycystic ovary syndrome; 4. Hyaluronic acid allergy; 5. Other conditions that the investigator considers ineligible for enrollment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-22 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |